and business
environments. These risks and uncertainties are described more fully in
Sangamo's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q as
filed with the Securities and Exchange Commission. Forward-looking
statements contained in this announcement are made as of this date and will
not be updated.
SELECTED FINANCIAL DATA
(in thousands, except per share data)
(unaudited)
Three Months Ended Six Months Ended
June 30, June 30,
2008 2007 2008 2007
Consolidated Statement of
Operations Data:
Revenues
Collaboration agreements $2,378 $1,461 $4,462 $2,611
Research grants 464 1,123 1,145 1,395
Total revenues 2,842 2,584 5,607 4,006
Operating expenses:
Research and development 8,286 6,309 16,929 11,739
General and administrative 2,545 2,113 5,472 4,112
Total operating expenses 10,831 8,422 22,401 15,851
Loss from operations (7,989) (5,838) (16,794) (11,845)
Interest income, net 570 657 1,406 1,305
Net loss $(7,419) $(5,181) $(15,388) $(10,540)
Basic and diluted net loss per
common share $(0.18) $(0.15) $(0.38) $(0.30)
Shares used in computing basic and
diluted net loss per common share 40,858 35,136 40,673 35,097
CONSOLIDATED CONDENSED BALANCE SHEET
DATA
June 30, 2008 December 31, 2007
Cash, cash equivalents, and
investments $64,295 $81,412
Total assets
'/>"/>
SOURCE Sangamo BioSciences, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 Related biology technology :1.
Sangamo BioSciences Announces Second Quarter Conference Call and Webcast2.
Sangamo BioSciences and Sigma-Aldrich Announce Research and License Agreement With Roche for the Use of ZFN Technology for Generation of Transgenic Animals3.
Dow AgroSciences Announces Early Exercise of Option for Commercial License With Sangamo BioSciences for Plants4.
Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestones in Plant Agriculture Collaboration5.
Sangamo BioSciences to Present at the Canaccord Adams Diabetes and Obesity Conference6.
Sangamo BioSciences Announces Presentation of Phase 1 Data of ZFP Therapeutic at International Society for Cellular Therapy (ISCT) Meeting7.
Sangamo BioSciences Nominates Thomas G. Wiggans to Its Board of Directors8.
Sangamo BioSciences Announces First Quarter Conference Call and Webcast9.
Sangamo BioSciences Announces License Agreement For the Use of ZFP Technology For Generation of Transgenic Animals10.
Sangamo BioSciences to Present at the Cowen and Company 28th Annual Health Care Conference11.
Sangamo BioSciences Announces Expansion of Research and License Agreement With Genentech for ZFP Technology for Protein Pharmaceutical Production